Bavarian in Talks to Sell Prostate Cancer Vaccine
This article is for subscribers only.
Bavarian Nordic A/S, the Danish drugmaker supplying the U.S. government with smallpox vaccines, gained the most in two weeks in Copenhagen trading after saying it’s in discussions to license its prostate cancer shot.
Several drugmakers, “including some of the largest,” are conducting due diligence on the product, which may extend men’s lives two times longer than Dendreon Corp.’s and Johnson & Johnson’s medicines, Bavarian Nordic said today in a statement.